- Home
- RLAY
as of 11-28-2025 12:39pm EST
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.0B | IPO Year: | 2020 |
| Target Price: | $16.00 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.77 - $8.36 | Next Earning Date: | 11-06-2025 |
| Revenue: | $8,355,000 | Revenue Growth: | -16.50% |
| Revenue Growth (this year): | 27.3% | Revenue Growth (next year): | 7.43% |
AI-Powered RLAY Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Relay Therapeutics Inc. (RLAY)
President and CEO
Avg Cost/Share
$7.00
Shares
62,073
Total Value
$434,511.00
Owned After
703,215
SEC Form 4
See remarks
Avg Cost/Share
$7.50
Shares
21,394
Total Value
$160,455.00
Owned After
337,469
SEC Form 4
President, R&D
Avg Cost/Share
$7.29
Shares
30,897
Total Value
$225,239.13
Owned After
521,823
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$7.29
Shares
21,664
Total Value
$157,930.56
Owned After
313,631
SEC Form 4
See remarks
Avg Cost/Share
$7.29
Shares
19,135
Total Value
$139,494.15
Owned After
337,469
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Patel Sanjiv | RLAY | President and CEO | Nov 3, 2025 | Sell | $7.00 | 62,073 | $434,511.00 | 703,215 | |
| Rahmer Peter | RLAY | See remarks | Oct 29, 2025 | Sell | $7.50 | 21,394 | $160,455.00 | 337,469 | |
| Bergstrom Donald A | RLAY | President, R&D | Oct 28, 2025 | Sell | $7.29 | 30,897 | $225,239.13 | 521,823 | |
| Catinazzo Thomas | RLAY | Chief Financial Officer | Oct 28, 2025 | Sell | $7.29 | 21,664 | $157,930.56 | 313,631 | |
| Rahmer Peter | RLAY | See remarks | Oct 28, 2025 | Sell | $7.29 | 19,135 | $139,494.15 | 337,469 |
Compare RLAY vs Leading Stocks
See how RLAY stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RLAY Relay Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.